Scholarlink

<p>Diabetes is a chronic metabolic disorder characterized by persistent hyperglycemia due to insufficient insulin production or impaired insulin response. Recent advances in nanotechnology offer innovative solutions for improving diabetes management, particularly through the use of starch nanoparticles (SNPs). SNPs have emerged as promising carriers for insulin delivery. Thanks to their biocompatibility, biodegradability, and ability to protect insulin from degradation in the gastrointestinal tract. The present review highlights the role of SNPs in enhancing insulin bioavailability, enabling sustained release via controlled delivery, and improving glucose regulation. Additionally, SNPs facilitate enzyme inhibition, particularly alpha-amylase, reducing postprandial glucose spikes and offering better glycemic control. The application of pH-responsive and glucose-sensitive SNP systems further enhances targeted insulin delivery, potentially mimicking the body’s natural glucose regulation mechanisms. These developments position SNPs as a key component in future diabetes therapies, offering less invasive, more efficient, easily metabolized, and patient-friendly treatment options. However, challenges such as scalability, stability, and long-term safety remain, warranting further research to optimize SNP-based therapies for clinical use.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Starch Nanoparticles (SNPs)-Based Therapeutics in Diabetes Treatment

  • 期刊论文

  • 发表日期：

    2025年10月15日

查看全文
  • Kiran Mishra,
  • Sophiya Babu,
  • Sharon Varghese,
  • Subhash Babu,
  • Sandeep Raja,
  • Aamir Hussain Dar,
  • Brajesh Pandey,
  • Veda Krishnan,
  • Bejoy Thomas

摘要

Diabetes is a chronic metabolic disorder characterized by persistent hyperglycemia due to insufficient insulin production or impaired insulin response. Recent advances in nanotechnology offer innovative solutions for improving diabetes management, particularly through the use of starch nanoparticles (SNPs). SNPs have emerged as promising carriers for insulin delivery. Thanks to their biocompatibility, biodegradability, and ability to protect insulin from degradation in the gastrointestinal tract. The present review highlights the role of SNPs in enhancing insulin bioavailability, enabling sustained release via controlled delivery, and improving glucose regulation. Additionally, SNPs facilitate enzyme inhibition, particularly alpha-amylase, reducing postprandial glucose spikes and offering better glycemic control. The application of pH-responsive and glucose-sensitive SNP systems further enhances targeted insulin delivery, potentially mimicking the body’s natural glucose regulation mechanisms. These developments position SNPs as a key component in future diabetes therapies, offering less invasive, more efficient, easily metabolized, and patient-friendly treatment options. However, challenges such as scalability, stability, and long-term safety remain, warranting further research to optimize SNP-based therapies for clinical use.